OR WAIT null SECS
Eight companies representing the pharmaceutical supply chain have joined a newly founded non-profit membership association, Alliance to Zero, aimed at facilitating the transition of the pharma sector to comply with net-zero emissions.
As reported on June 2, 2021, eight companies representing the pharmaceutical supply chain have joined a newly founded non-profit membership association, Alliance to Zero, which is aimed at facilitating the transition of the pharma sector to comply with net-zero emissions in line with the Paris Climate Agreement.
The founding members of the alliance include Sharp, Harro Höfliger, Schreiner MediPharm, Körber Pharma, Schott, Health Beacon, Datwyler, and Ypsomed, which represent key parts of the pharma supply chain. All members share the view that collaboration across the pharmaceutical supply chain is needed urgently to reduce the manufacturing emissions footprint.
“The formation of this alliance is the first step in a challenging but urgent journey that our member organizations have committed themselves to,” said Sebastian Gerner, president of the Alliance to Zero, in the press release. “Enabling the launch of net-zero pharmaceutical products in regulated markets will require companies like ours to transform our operations, products, services, logistics, innovations, and investments. Our combined effort and our shared responsibility to ensure a real and lasting change is at the heart of the Alliance’s mission.”
A roadmap describing what a net-zero emission concept for pharmaceutical manufacturing and supply chain might look like is already being developed by the alliance. This roadmap will also lay out the steps that are necessary for the industry to achieve the goal of net-zero emissions.
Source: Alliance to Zero